Clinical Investigation

Japanese Journal of Ophthalmology

, Volume 53, Issue 2, pp 125-130

First online:

Comparing outcomes in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration treated with two different doses of primary intravitreal bevacizumab: results of the pan-american collaborative retina study group (PACORES) at the 12-month follow-up

  • Lihteh WuAffiliated withInstituto de Cirugia Ocular Email author 
  • , J. Fernando ArevaloAffiliated withRetina and Vitreous Service, Clinica Oftalmológica Centro Caracas
  • , Mauricio MaiaAffiliated withDepartamento de Oftalmologia, Instituto da Visão, Universidade Federal de São Paulo
  • , Maria H. BerrocalAffiliated withUniversity of Puerto Rico
  • , Juan SanchezAffiliated withRetina and Vitreous Service, Clinica Oftalmológica Centro Caracas
  • , Teodoro EvansAffiliated withInstituto de Cirugia Ocular
  • , the Pan-American Collaborative Retina Study Group (PACORES)

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Purpose

To compare the total number of injections and the anatomic and best-corrected visual acuity (VA) response after injecting 1.25 or 2.5 mg of bevacizumab as needed in patients with primary choroidal neovascularization secondary to age-related macular degeneration (AMD) at 12 months.

Methods

This was a retrospective, interventional, comparative multicenter study of 60 eyes treated with intravitreal bevacizumab (35 eyes, 1.25 mg; 25 eyes, 2.5 mg).

Results

The mean number of injections per eye was 3.8 in the 1.25-mg group and 3.2 in the 2.5-mg group (P = 0.2752). At 12 months, in the 1.25-mg group, 16 (46%) eyes gained ≥3 lines of Early Treatment Diabetic Retinopathy Study (ETDRS) VA and seven (20%) lost ≥3 lines of ETDRS VA. In the 2.5-mg group, 11 (44%) eyes improved by ≥3 lines, and four (16%) lost ≥3 lines (P = 1.000). At 12 months, in the 1.25-mg group, the mean central macular thickness decreased from 419 ± 201 μm at baseline to 268 ± 96 μm, compared with a decrease from 388 ± 162 to 296 ± 114 μm in the 2.5-mg group (P = 0.7896).

Conclusion

There were no statistically significant differences between the two dose groups with regard to the number of injections, anatomic and VA outcomes.

Key Words

age-related macular degeneration bevacizumab choroidal neovascularization VEGF